Trace Launches With $101m To Pursue ALS Drug Based On Genomic Insights
Could Address Up To 97% Of Patients
Trace Neuroscience will take its antisense oligonucleotide that restores UNC13A protein production through proper mRNA splicing into the clinic in early 2026.
